Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

The in vitro bacterial viability and microbial composition of commercially available canine and feline fecal microbial transplantation products

Created on 12 Nov 2025

Authors

Randolph, N. K., Wetzel, L., Diaz-Campos, D., van Balen, J. C., Winston, J. A.

Abstract

Fecal microbial transplantation (FMT) is the transfer of feces from a healthy donor into the gastrointestinal tract of a diseased recipient to confer a health benefit. FMT is increasingly utilized in veterinary medicine and is offered commercially by AnimalBiomeTM. This study aims to quantitate the colony forming units per gram (CFU/g) in lyophilized AnimalBiomeTM FMT products compared to fresh and lyophilized in-house FMT; and to evaluate microbial compositions across multiple FMT products. FMT products were cultured in aerobic and anaerobic environments. 16s rRNA amplicon sequencing (V4 region) was performed on FMT products and colonies taken from FMT cultures. Three lots each of AnimalBiomeTM DoggyBiomeTM (DB), DoggyBiomeTM from raw fed dogs (DBR), and KittyBiomeTM (KB) were evaluated. Freshly processed stool from screened donors enrolled in The Ohio State University Companion Animal Fecal Bank (CAFB) were used as controls. Freshly processed feces yielded significantly greater total CFU/g compared to all lyophilized products (dogs, P<0.01; cats, P<0.01). KB and feline CAFB lyophilized products exhibited comparable viability (P=0.14). Canine CAFB lyophilized FMT yielded significantly greater CFU/g than DB (P=0.17) and DBR (P=0.018). Each donor has a unique microbial profile (PERMANOVA; dogs, P=0.001; cats, P=0.03). DBR FMT products have a significantly greater abundance of Enterobacteriaceae compared to other canine products (P<0.01); however, no AnimalBiomeTM product showed detectable growth of Gram-negative microbes. These findings will provide evidence for practitioners when choosing FMT products for their patients. Further research is needed to determine the impact of FMT processing on engraftment and clinical outcome.

Preprint server: bioRxiv
The authors list and abstract were imported from bioRxiv on 12 Nov 2025.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this preprint? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 32
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement